Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01)
Cyclobenzaprine Hydrochloride
Product Images NDC 53002-3080
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Cyclobenzaprine Hydrochloride (NDC 53002-3080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)
This is a description of the side effects of Cyclobenzaprine HCI tablets at 5mg and 10mg doses, as compared to a placebo. The side effects that were observed and their percentages are listed, including drowsiness, dry mouth, fatigue, and headache. The data is broken down by dosage and compared to the placebo.*
Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)
This text appears to be a report on clinical studies and a surveillance program conducted with Cyclobenzaprine HCl tablets. The studies and program reveal the following percentages of side effects: drowsiness at 39%, dry mouth at 2%, and dizziness at 1%. The surveillance program showed a 16% rate of adverse reactions and a 7% incidence of drowsiness, and 3% incidence of dry mouth.*
Label Image (Lbl530023080)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
